不幸的是，并非所有转移性去势抵抗性前列腺癌 (mCRPC) 患者都能接受可用的延长生命的全身治疗，这强调了优化 mCRPC 治疗选择的必要性。需要更好的指南来确定前列腺癌的基因检测。在这本由两部分组成的基于专家意见的指南中，我们提供了关于利用种系和体细胞检测来检测 mCRPC 患者 HRR 改变的专家共识意见。本指南由 2023-2024 年召集的多学科专家小组制定，其中包括来自肿瘤内科、泌尿科、放射肿瘤科、病理学、医学基因组学和基础科学的代表。在第二部分中，我们重点介绍基因检测如何改善、延长生命的 mCRPC 治疗策略，基于对 mCRPC 中 PARP 抑制剂最近 III 期试验的回顾以及随后监管部门的批准。© 2024。作者。

Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer.In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science.In this second part, we highlight how genetic testing can lead to improved, life-prolonging mCRPC therapeutic strategies based on a review of the recent phase III trials and subsequent regulatory approvals for PARP inhibitors in mCRPC.© 2024. The Author(s).